Neuroprotective effects of fingolimod in mouse models of Parkinson's disease

FASEB Journal

Volumn 31, Issue 1, 2017, Pages 172-179

  Zhao, Peng ^a   Yang, Xiaoxia ^a   Yang, Liu ^a   Li, Minshu ^a,b   Wood, Kristofer ^b   Liu, Qiang ^a,b   Zhu, Xiaodong ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Neuroprotection; Neurotoxicity; S1pr

Indexed keywords

CASPASE 3; DOPAMINE; FINGOLIMOD; LYSOPHOSPHOLIPID RECEPTOR AFFECTING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOPAMINE; ROTENONE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; W 146; NEUROPROTECTIVE AGENT; S1PR1 PROTEIN, HUMAN; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METABOLITE; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROBLASTOMA; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FINGOLIMOD HYDROCHLORIDE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RECEPTORS, LYSOSPHINGOLIPID; ROTENONE;

EID: 85009819800     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201600751R     Document Type: Article

References (33)

1. Damier, P., Hirsch, E. C., Agid, Y., and Graybiel, A. M. (1999) The substantia nigra of the human brain, II: patterns of loss of dopaminecontaining neurons in Parkinson's disease. Brain 122, 1437-1448.
2. Olanow, C.W., and Schapira, A.H. (2013) Therapeutic prospects for Parkinson disease. Ann. Neurol. 74, 337-347.
3. Abbott, A. (2010) Levodopa: the story so far. Nature 466, S6-S7.
4. Athauda, D., and Foltynie, T. (2015) The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat. Rev. Neurol. 11, 25-40.
5. Hannun, Y. A., and Obeid, L. M. (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9, 139-150.
6. Pyszko, J., and Strosznajder, J. B. (2014) Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4- phenylpyridinium (MPP+) in human dopaminergic neuronal cells. Mol. Neurobiol. 50, 38-48.
7. Sivasubramanian, M., Kanagaraj, N., Dheen, S. T., and Tay, S. S. (2015) Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons ofmousemodel of Parkinson's disease and in MPP+ -treated MN9D cells in vitro. Neuroscience 290, 636-648.
8. Deogracias, R., Yazdani, M., Dekkers, M. P., Guy, J., Ionescu, M. C., Vogt, K. E., and Barde, Y. A. (2012) Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. USA 109, 14230-14235.
9. Colombo, E., Di Dario, M., Capitolo, E., Chaabane, L., Newcombe, J., Martino, G., and Farina, C. (2014) Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann. Neurol. 76, 325-337.
10. Schapira, A. H., and Tolosa, E. (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6, 309-317.
11. Burte, F., Carelli, V., Chinnery, P. F., and Yu-Wai-Man, P. (2015) Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat. Rev. Neurol. 11, 11-24.
12. Beal, M. F. (2001) Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 325-334.
13. Blandini, F., and Armentero, M. T. (2012) Animal models of Parkinson's disease. FEBS J. 279, 1156-1166.
14. Duty, S., and Jenner, P. (2011) Animalmodels of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 164, 1357-1391.
15. Tieu, K. (2011) A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb. Perspect. Med. 1, a009316.
16. Bove, J., and Perier, C. (2012) Neurotoxin-based models of Parkinson's disease. Neuroscience 211, 51-76.
17. Da Conceicao, F. S., Ngo-Abdalla, S., Houzel, J. C., and Rehen, S. K. (2010)Murine model for Parkinson's disease: from 6-OH dopamine lesion to behavioral test. J. Vis. Exp. 35, 1376.
18. Gan, Y., Liu, Q., Wu, W., Yin, J. X., Bai, X.F., Shen, R., Wang, Y., Chen, J., La Cava, A., Poursine-Laurent, J., Yokoyama, W., and Shi, F. D. (2014) Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc.Natl. Acad. Sci. USA 111, 2704-2709.
19. Liu, Q., Sanai, N., Jin, W. N., LaCava, A., Van Kaer, L., and Shi, F. D. (2016) Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat. Neurosci. 19, 243-252.
20. Jin, W. N., Yang, X., Li, Z., Li, M., Shi, S. X., Wood, K., Liu, Q., Fu, Y., Han, W., Xu, Y., Shi, F.D., andLiu, Q. (2016)Non-invasivetrackingof CD4+ T cells with a paramagnetic and fluorescent nanoparticle in brain ischemia. J. Cereb. Blood Flow Metab. 36, 1464-1476.
21. Liu, Q., Xie, X., Lukas, R. J., St John, P. A., and Wu, J. (2013) A novel nicotinic mechanism underlies b-amyloid-induced neuronal hyperexcitation. J. Neurosci. 33, 7253-7263.
22. Liu, Q., Huang, Y., Xue, F., Simard, A., DeChon, J., Li, G., Zhang, J., Lucero, L., Wang, M., Sierks, M., Hu, G., Chang, Y., Lukas, R. J., and Wu, J. (2009)Anovelnicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J. Neurosci. 29, 918-929.
23. Liu, Q., Tang, Z., Gan, Y., Wu, W., Kousari, A., La Cava, A., and Shi, F. D. (2014) Genetic deficiency of b2-containing nicotinic receptors attenuates brain injury in ischemic stroke. Neuroscience 256, 170-177.
24. Gong, L., Zhang, Q. L., Zhang, N., Hua, W. Y., Huang, Y. X., Di, P.W., Huang, T., Xu, X. S., Liu, C. F., Hu, L. F., and Luo, W. F. (2012) Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3b signaling pathway. J. Neurochem. 123, 876-885.
25. Liu, Q., Xie, X., Emadi, S., Sierks, M. R., and Wu, J. (2015) A novel nicotinic mechanism underlies b-amyloid-induced neurotoxicity. Neuropharmacology 97, 457-463.
26. Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M., and Lynch, K. R. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453-21457.
27. Dev, K.K., Mullershausen, F., Mattes, H., Kuhn, R.R., Bilbe, G., Hoyer, D., and Mir, A. (2008) Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol. Ther. 117, 77-93.
28. Hasegawa, Y., Suzuki, H., Sozen, T., Rolland, W., and Zhang, J. H. (2010)Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 41, 368-374.
29. Sun, N., Shen, Y., Han, W., Shi, K., Wood, K., Fu, Y., Hao, J., Liu, Q., Sheth, K.N., Huang, D., and Shi, F. D. (2016) Selective sphingosine-1- phosphate receptor 1 modulation attenuates experimental intracerebral hemorrhage. Stroke 47, 1899-1906.
30. Cipriani, R., Chara, J. C., Rodŕiguez-Antiguedad, A., and Matute, C. (2015) FTY720 attenuates excitotoxicity and neuroinflammation. J. Neuroinflammation 12, 86.
31. Choi, J.W., Gardell, S. E., Herr, D.R., Rivera, R., Lee, C.W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., and Chun, J. (2011) FTY720 (fingolimod) efficacy in an animal model ofmultiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc.Natl. Acad. Sci. USA 108, 751-756.
32. Guadaño, A., Gonźalez-Coloma, A., and de la Peña, E. (1998) Genotoxicity of the insecticide rotenone in cultured human lymphocytes. Mutat. Res. 414, 1-7.
33. Avila-Gomez, I. C., Velez-Pardo, C., and Jimenez-Del-Rio, M. (2010) Effects of insulin-like growth factor-1 on rotenone-induced apoptosis in human lymphocyte cells. Basic Clin. Pharmacol. Toxicol. 106, 53-61.